scholarly journals 209.5: Microvessels Support the In Vivo Engraftment and Function of Pancreatic Cells in Cell Replacement Therapy

2021 ◽  
Vol 105 (12S1) ◽  
pp. S15-S15
Author(s):  
Yasaman Aghazadeh ◽  
Frankie Poon ◽  
Farida Sarangi ◽  
Sara S. Nunes ◽  
Maria Cristina Nostro
Keyword(s):  
Replacement Therapy ◽  
Cell Replacement Therapy ◽  
Cell Replacement ◽  
Pancreatic Cells ◽  
And Function

Medium spiny neurons for transplantation in Huntington's disease

2009 ◽  
Vol 37 (1) ◽  
pp. 323-328 ◽  
Author(s):  
Claire M. Kelly ◽  
Stephen B. Dunnett ◽  
Anne E. Rosser
Keyword(s):  
Huntington's Disease ◽  
Replacement Therapy ◽  
Huntington’S Disease ◽  
Ethical Issues ◽  
Medium Spiny Neuron ◽  
Cell Replacement Therapy ◽  
Potential Donor ◽  
Cell Replacement ◽  
And Function

Cell-replacement therapy for Huntington's disease is one of very few therapies that has reported positive outcomes in clinical trials. However, for cell transplantation to be made more readily available, logistical, standardization and ethical issues associated with the current methodology need to be resolved. To achieve these goals, it is imperative that an alternative cell source be identified. One of the key requirements of the cells is that they are capable of acquiring an MSN (medium spiny neuron) morphology, express MSN markers such as DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa), and function in vivo in a manner that replicates those that have been lost to the disease. Developmental biology has progressed in recent years to provide a vast array of information with regard to the key signalling events involved in the proliferation, specification and differentiation of striatal-specific neurons. In the present paper, we review the rationale for cell-replacement therapy in Huntington's disease, discuss some potential donor sources and consider the value of developmental markers in the identification of cells with the potential to develop an MSN phenotype.

scholarly journals Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells

2019 ◽  
Vol 2 ◽  
pp. 100006 ◽  
Author(s):  
D.C. Oran ◽  
T. Lokumcu ◽  
Y. Inceoglu ◽  
M.B. Akolpoglu ◽  
O. Albayrak ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Beta Cell ◽  
Replacement Therapy ◽  
Stellate Cells ◽  
Cell Replacement Therapy ◽  
Cell Replacement ◽  
Beta Cell Replacement

scholarly journals In Vivo Differentiation of Mouse Embryonic Stem Cells into Hepatocytes

2002 ◽  
Vol 11 (4) ◽  
pp. 359-368 ◽  
Author(s):  
Dongho Choi ◽  
Hyun-Jeong Oh ◽  
Uck-Jin Chang ◽  
Soo Kyung Koo ◽  
Jean X. Jiang ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Es Cells ◽  
Embryonic Stem ◽  
Cell Replacement Therapy ◽  
Differentiation Potential ◽  
Cell Replacement ◽  
Mouse Es Cells ◽  
Cord Injury ◽  
In Vivo Differentiation

Embryonic stem (ES) cells have been regarded as a powerful resource for cell replacement therapy. In recent reports mouse ES cells have been successfully applied in the treatment of spinal cord injury, hereditary myelin disorder of the central nervous system, and diabetes mellitus. Another type of disease that could benefit from the availability of stem cell therapy is liver disease. However, for this potential to be realized, it is necessary to demonstrate the differentiation of ES cells into hepatocytes. To demonstrate the in vivo differentiation potential of mouse ES cells, we injected ES cells into the spleen of immunosuppressed nude mice. Histological analysis of teratomas derived from injected ES cells revealed that some areas contained typical hepatocytes arranged in a sinusoidal structure. The hepatic nature of these cells was further confirmed by showing that transcripts of liver-specific genes were present in the differentiated teratoma using reverse transcriptase-polymerase chain reaction and immunohistochemistry using several liver-specific antibodies including HEP-PAR, phenylalanine hydroxylase, and mouse N-system aminotransferase to identify the respective proteins in the differentiated hepatocytes. This is the first demonstration that mouse ES cells can differentiate in vivo into a mixed population of hepatocytes of varying maturity. This finding extends the potential use of ES cells in the cell replacement therapy by including its possible application for treating liver diseases.

A microfluidic platform enables comprehensive gene expression profiling of mouse retinal stem cells

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Shana O Kelley ◽  
Mahmoud Labib ◽  
Brenda Coles ◽  
Mahla Poudineh ◽  
Brendan Innes ◽  
...  
Keyword(s):  
Gene Expression ◽  
Stem Cells ◽  
Stem Cell ◽  
Visual Impairment ◽  
Gene Expression Profiling ◽  
Replacement Therapy ◽  
Retinal Degeneration ◽  
Expression Profiling ◽  
Cell Replacement Therapy ◽  
Cell Replacement

Loss of photoreceptors due to retinal degeneration is a major cause of untreatable visual impairment and blindness. Cell replacement therapy, using retinal stem cell (RSC)-derived photoreceptors, holds promise for reconstituting...

scholarly journals ENTPD3 Marks Mature Stem Cell Derived Beta Cells Formed by Self-Aggregation in Vitro

2021 ◽  
Author(s):  
Fiona M. Docherty ◽  
Kent A. Riemondy ◽  
Roberto Castro-Gutierrez ◽  
JaeAnn M. Dwulet ◽  
Ali H. Shilleh ◽  
...  
Keyword(s):  
Stem Cell ◽  
Replacement Therapy ◽  
Beta Cells ◽  
Nucleoside Triphosphate ◽  
Specific Marker ◽  
Detailed Knowledge ◽  
Cell Replacement Therapy ◽  
Mature Adult ◽  
Cell Replacement

Stem cell derived beta-like cells (sBC) carry the promise of providing an abundant source of insulin-producing cells for use in cell replacement therapy for patients with diabetes, potentially allowing widespread implementation of a practical cure. To achieve their clinical promise, sBC need to function comparably to mature adult beta cells, but as yet they display varying degrees of maturity. Indeed, detailed knowledge of the events resulting in human beta cell maturation remains obscure. Here we show that sBC spontaneously self-enrich into discreet islet-like cap structures within <i>in vitro</i> cultures, independent of exogenous maturation conditions. Multiple complementary assays demonstrate that this process is accompanied by functional maturation of the self-enriched sBC (seBC); however, the seBC still contain distinct subpopulations displaying different maturation levels. Interestingly, the surface protein ENTPD3 (also known as nucleoside triphosphate diphosphohydrolase-3 (NDPTase3)) is a specific marker of the most mature seBC population and can be used for mature seBC identification and sorting. Our results illuminate critical aspects of <i>in vitro</i> sBC maturation and provide important insights towards developing functionally mature sBC for diabetes cell replacement therapy.

Sign in / Sign up

Export Citation Format

Share Document